Intelligent Bio Solutions (INBS) said Thursday that it expects to get its sixth US patent, which would enhance the protection of its lateral flow technology, which is key to intelligence fingerprinting drug testing.

The expected patent grant would enhance Intelligent Bio's current intellectual property portfolio as it prepares to enter the US market this year, the medical technology company said.

Shares of Intelligent Bio were up nearly 4% in recent Thursday premarket activity.